Trials / Completed
CompletedNCT00328120
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
An Open, Multicentre Phase I Clinical Study to Assess the Tolerability of Fulvestrant 500 mg in Postmenopausal Women With Hormone Receptor Positive Advanced or Recurrent Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fulvestrant | 500 mg intramuscular injection |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2006-04-01
- Completion
- 2010-06-01
- First posted
- 2006-05-19
- Last updated
- 2010-11-17
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00328120. Inclusion in this directory is not an endorsement.